<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119595</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-2043</org_study_id>
    <nct_id>NCT05119595</nct_id>
  </id_info>
  <brief_title>PMCF Study on CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures</brief_title>
  <acronym>CRANFLAP</acronym>
  <official_title>Prospective, Single Center PMCF-study on the Performance and Safety of the CranioFix®2 System Used for the Fixation of Craniotomized Bone Flaps and Fractures to the Neurocranium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CranioFix®2 PMCF study has been set up as an action within the framework of a proactive&#xD;
      post-market surveillance system of the manufacturer. The aim of this observational study is&#xD;
      to collect systematically and proactively data regarding the performance of CranioFix®2, like&#xD;
      adverse events (AEs), handling and cosmetic outcome, under daily clinical practice when used&#xD;
      as intended by the manufacturer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone flap planarity after implantation (Comparison of planarity at two time points)</measure>
    <time_frame>Through postoperative course: at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)</time_frame>
    <description>Rate of patients in which a dislocation of the bone flap occurs (defined as the height of the tilting (depression / protrusion) greater than the bone width</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events during the study</measure>
    <time_frame>through study completion, an average of 3 months</time_frame>
    <description>Number of adverse events e.g. foreign body reactions, infections, injury to the dura, injury to the scalp, epiduralhaematoma, wound healing disorders with special focus on (serious) adverse events with (possible) relation to the investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handling of CranioFix®2 system</measure>
    <time_frame>intraoperative</time_frame>
    <description>Assessment of handling, documented on a Likert scale 1 to 5 (1 is the best, 5 is the worst result)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of the bone flap after fixation</measure>
    <time_frame>intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)</time_frame>
    <description>Assessment of stability of the bone flap intraoperatively and at postoperative follow-up, documented on a Likert scale 1 to 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome</measure>
    <time_frame>intraoperative, at discharge (about up to 2 weeks after surgery) and post-operative follow-up (3±2 months)</time_frame>
    <description>Assessment of cosmetic outcome intraoperatively, at discharge and at post-operative follow-up documented on a 3 point scale (good, fair, bad)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Skull Fractures</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients enrolled will be prospectively examined according to the study plan until&#xD;
        follow-up examination (depending on routine in clinic).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Use of CranioFix®2 system according to IfU&#xD;
&#xD;
          -  Planned postoperative MRI within clinical routine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with hypersensitivity to metals or allergies to the implant materials&#xD;
&#xD;
          -  Inflammations in the region of the implant site&#xD;
&#xD;
          -  Bone conditions that rule out the application of CranioFix®2 titanium clamps&#xD;
&#xD;
          -  Use with artificial cranial bone flaps&#xD;
&#xD;
          -  Bone tumors in the area supporting the implant&#xD;
&#xD;
          -  Degenerative bone diseases&#xD;
&#xD;
          -  Missing dura mater&#xD;
&#xD;
          -  Application in the facial skull (viscerocranium) and in the orbital or skull-base&#xD;
             region&#xD;
&#xD;
          -  Combination of implant components from different manufacturers, i.e. additional use of&#xD;
             plates and screws on the same bone fragment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Franziska Greifzu, Dr.</last_name>
    <phone>+49-7461-95-</phone>
    <phone_ext>0</phone_ext>
    <email>franziska.greifzu@aesculap.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Minou Nadji-Ohl, Dr.</last_name>
      <phone>+49-711-278</phone>
      <phone_ext>01</phone_ext>
    </contact>
    <investigator>
      <last_name>Minou Nadji-Ohl, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone Flap Fixation</keyword>
  <keyword>Fractures to the Neurocranium</keyword>
  <keyword>Craniotomized bone flaps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skull Fractures</mesh_term>
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

